Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.50 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763698 | 0.97 | JMJD6 (0.64) | JMJD6MAPTLMNATP53THRB | |
| SCHEMBL4763737 | 0.88 | JMJD6 (0.61) | JMJD6MAPTLMNATP53THRB | |
| SCHEMBL811785 | 0.88 | JMJD6 (0.76) | JMJD6KDM4EKDM6BKDM5CKDM4C | |
| SCHEMBL30171421 | 0.88 | JMJD6 (0.76) | JMJD6KDM4EKDM6BKDM5CKDM4C | |
| SCHEMBL31417865 | 0.86 | JMJD6 (0.56) | JMJD6MAPTLMNATP53THRB | |
| SCHEMBL4770697 | 0.86 | JMJD6 (0.59) | JMJD6MAPTLMNATP53THRB | |
| SCHEMBL4768876 | 0.86 | JMJD6 (0.59) | JMJD6MAPTLMNATP53THRB | |
| SCHEMBL30614246 | 0.85 | JMJD6 (0.65) | JMJD6LMNANPC1RAB9AKDM4E | |
| SCHEMBL2301563 | 0.85 | JMJD6 (0.65) | JMJD6LMNANPC1RAB9AKDM4E | |
| SCHEMBL28332640 | 0.85 | JMJD6 (0.61) | JMJD6MAPTLMNATP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053815-B | Iridium (III) complex and preparation method and application thereof | 南京工业大学 | 2019-12-10 | — | — | CN | claimed |
| CN-109053815-B | Iridium (III) complex and preparation method and application thereof | 南京工业大学 | 2019-12-10 | — | — | CN | disclosed |
| CN-109053815-B | Iridium (III) complex and preparation method and application thereof | 南京工业大学 | 2019-12-10 | — | — | CN | disclosed |
| CN-109053815-A | Iridium (III) complex and preparation method and application thereof | 南京工业大学 | 2018-12-21 | — | — | CN | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1400513-B1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | KOWA CO (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1400513-A1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6552188-B2 | Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds | KOWA CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | H1-0, DDAH1, AOC1 | JMJD6 1967/4885MAPT 4305/4885LMNA 2188/4885 |
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | JMJD6 2527/4885MAPT 3631/4885LMNA 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.